Recruiting

aDBS

Sponsor:

UCLA

Code:

NCT07288437

Conditions

Spinocerebellar Ataxia (SCA)

Spinocerebellar Ataxia Type 6

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Interventions

Deep Brain Stimulation (DBS)

Study Details

Brief summary:

The goal of this clinical trial is to test the safety of placing Deep Brain Stimulators (DBS) in the cerebellum and using electrical stimulation of that part of the brain to treat symptoms related to the participants spinocerebellar ataxia. Five adults diagnosed with spinocerebellar ataxia type 6 (SCA6) with inadequate cerebellar symptom relief will be implanted with a Medtronic Percept Primary Cell Neurostimulator. The device will be implanted into the dentate nucleus, which is a structure located within the cerebellum that is responsible for controlling movement and balance.

Specifically, the investigators will be using adaptive deep brain stimulation (aDBS), which analyzes brain signals and automatically adjusts the strength, timing, and pattern of stimulation according to the patient's needs at any given moment. This study will evaluate the feasibility, safety, and tolerability of aDBS in SCA6 patients.

Conditions

Spinocerebellar Ataxia (SCA)

Spinocerebellar Ataxia Type 6

Study ID

NCT07288437

Start date

Apr 27, 2026

Status verified date

Dec, 2025

Completion date

Mar, 2031

Anticipated

Primary completion date

Mar, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. A diagnosis of SCA6 by a Movement Disorders specialist following established criteria recommended by the Movement Disorders Society.
2. A positive genetic test for SCA6.
3. A total scale ≥ 8 on the Scale of the Assessment and Rating of Ataxia (SARA) rating scale.
4. Ability to walk with or without support (score < 8 on the 'gait' subsection of the SARA rating scale).
5. Age ≥ 21 years and < 89 years.
6. Ability to give informed consent for the study.
7. Be able to understand the study protocol.

Exclusion Criteria:

1. Inability or unwillingness to comply with the study protocol.
2. History of previously implanted neurostimulators, pacemakers, defibrillators, or metallic head implants.
3. Severe cognitive impairment or dementia, defined as a score < 21 on the Montreal Cognitive Assessment (MoCA).
4. Evidence of ataxia due to other etiologies, including but not limited to:

1. Genetic/inherited disorders other than SCA6.
2. Acquired causes: tramautic brain injury, multiple sclerosis, paraneplastic cerebellar degeneration, infections or post-infectious cerebellitis, autoimmune ataxias (e.g., anti-GAD, gluten ataxia).
3. Toxic/metabolic causes: alcoholic cerebellar degeneration, vitamin deficiencies.
4. Structural, vascular, or neoplastic causes: cerebellar stroke, tumors, congenital malformations.
5. Suspected multiple system atrophy-cerebellar type (MSA-C).
5. The presence of active and untreated psychiatric illness, severe depression (Beck Depression Inventory ≥ 21), or personality disorder at the discretion of the study team.
6. Coagulopathy, uncontrolled epilepsy, or other medical condition considered to place the patient at elevated risk for surgical complications. Presence of a concomitant medical condition that, in the investigator's opinion, may interfere with the study participation or gait/balance, for example, severe arthritis.
7. Presence of a concominant medical condition that, in the investigator's opinion, may interfere with the study participation or gait/balance, for example, severe arthritis.
8. Requirement of diathermy, electroconvulsive therapy, or transcranial magnetic stimulation.
9. Pregnancy or lactation.
10. Active suicidal ideation, defined as fined as a "Yes" response to questions #2-5 on the Columbia Suicide Severity Rating Scale, C-SSRS.
11. Refractory Epilepsy.

Study Design

Enrollment

5 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Adaptive Deep Brain Stimulation (aDBS)

One month after patients undergo DBS surgery in the cerebellum, conventional deep brain stimulation (cDBS) programming will begin to identify stimulation parameters (such as amplitude, contact, frequency, and pulse width) and ensure no adverse wide effects are witness. This phase also allows the study team to make sure device and electrode placement are working as intended. About nine months after implantation, the investigators will switch system settings over to aDBS to evaluate the feasibility, safety, and tolerability in the dentate nucleus of the cerebellum. Symptoms and side effects will be assessed by patients' self-reports, validated clinical scales, and wearable devices, which will be used to track movements and sleep data.

Interventions

Deep Brain Stimulation (DBS)

This device will be surgically implanted into the dentate nucleus of the cerebellum.

Primary outcome measure

  • Average total score for the Assessment and Rating of Ataxia (SARA) [ Time Frame: From baseline through study completion, about 2 years. ]
  • Average total Patient-Reported Outcome Measure of Ataxia (PROM-Ataxia) Score [ Time Frame: From baseline through study completion, about 2 years. ]

Central Contacts and Locations

Central contacts

Marta San Luciano Palenzuela, MD, PhD

(415) 353-2311Marta.SanLucianoPalenzuela@ucsf.edu

Karson J Franjieh, BS

415-755-8954karson.franjieh@ucsf.edu

Locations

UCSF Weill Institute for Neurosciences

Recruiting

San Francisco, California, United States, 94158

More Information

Sponsor

University of California, San Francisco

Last update posted

Jul 13, 2026

Last verified

Dec, 2025

Keywords

  • adaptive deep brain stimulation
  • aDBS
  • Spinocerebellar Ataxia
  • Spinocerebellar Ataxia Type 6
  • SCA6
  • DBS
  • deep brain stimulation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-07-13.